|
Description
QRxPharma (ASX: QRX), Sydney, Australia, has announced that a number of patients have been treated in the first of several clinical studies to be conducted as part of the Phase III development program for its lead product candidate Q8003IR, an immediate release dual-opioid pain therapy.
The initial clinical trial is a double-blind, placebo-controlled study designed to compare the efficacy and safety of four different dosage strengths of Q8003IR... |
More articles from Worldwide Biotech
MARKETING APPLICATION FOR VORINOSTAT FILED IN EUROPE., January 01, 2008
OASMIA PHARMACEUTICAL SIGNS LICENSING PACT WITH ORION., January 01, 2008
FOVEA/GENZYME SIGN OPHTHALMOLOGY RESEARCH PACT., January 01, 2008
HEALTH CANADA ACCEPTS SANTHERA'S NDS FOR SNT-MC17., January 01, 2008
Looking for additional articles?
Click here
to search our database of over 3 million articles.
|
